SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending as its dedicated community relentlessly builds a unique permissionless brand, marked by ongoing real-world product development including Kendu Spice and diverse entertainment initiatives. This bullish, active community is consistently recognized across crypto platforms for its 

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense investor scrutiny following its recent earnings report, with the stock experiencing significant after-hours volatility despite an earnings beat. Community sentiment is largely divided, balancing the long-term strategic potential of the proposed Warner Bros. Discovery acquisition and its associated intellectual property against concerns over a pause in share buybacks and a cautious outlook. Discussions are heavily focused on whether current price levels represent a significant buying opportunity or signal further downside amidst an evolving competitive streaming environment.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is surging on the back of severe cold weather forecasts, including polar vortex threats, driving expectations for increased natural gas demand and significant storage withdrawals across the U.S. and Europe. The community is actively discussing a potential short squeeze amid rallying natural gas futures, though many are also highlighting the commodity's notorious volatility and the potential for a swift reversal.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst significant downward pressure, pushing its RSI to historically oversold levels reminiscent of major market downturns and sparking intense debate among traders. While many in the community point to technical breakdowns and broader geopolitical concerns, others anticipate a sharp rebound ahead of upcoming earnings, citing strong iPhone demand and a strategic AI roadmap. This creates a sharply divided sentiment on whether the current dip is a buying opportunity or signals further downside.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial data for its oral eczema drug, soquelitinib, which showed significant skin improvement and a favorable safety profile, even in patients resistant to other therapies. The community is buzzing about its potential as a game-changer in a large market, leading to speculation about future partnerships or a buyout, though some are anticipating a potential share offering following the rapid appreciation.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is trending due to a strategic private placement by Medtronic complementing a recent public offering, sparking significant community speculation about potential future upside and acquisition. This excitement is further fueled by the company's recent commencement of its pivotal DurAVR heart valve trial, with many viewing the stock as currently undervalued.

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is gaining significant attention following its strategic partnership with Noveon Magnetics to establish a domestic U.S. supply chain for rare earth permanent magnets, a move strongly supported by broader geopolitical initiatives to reduce reliance on foreign supply. The community is keenly anticipating the upcoming quarterly results for further insights, viewing Lynas as a crucial player positioned to benefit from the tightening global rare earths market amidst increasing demand and strategic government focus on critical minerals.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is actively trending as the community highlights its strategic moves to dominate rare earth production outside China, including a significant acquisition and an updated feasibility study confirming strong economics for its processing expansion. Investors are discussing this as a transformational step towards securing critical minerals for clean energy and AI, reinforcing U.S. energy independence, though some debate its valuation after a rapid run.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid key strategic announcements, including a significant expansion with HD Hyundai in South Korea and a role in building next-gen AI infrastructure across EMEA. CEO Alex Karp's prominent presence at Davos, highlighting AI-driven efficiency and impact, fuels a strong bullish narrative among some investors. Conversely, the community remains divided on its lofty valuation, with others anticipating pullbacks and monitoring broader market volatility.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is trending due to pre-earnings anticipation, with investors evaluating the strength of its innovative medicine and MedTech segments amid ongoing legal challenges. Community sentiment is sharply divided, balancing optimism about JNJ's diversified portfolio and recent pipeline successes against concerns over the significant financial implications from persistent talc litigation and recent unfavorable court outcomes. The market closely watches how the healthcare leader manages both its growth initiatives and its expanding legal liabilities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a clinical master supply agreement with Swiss healthcare company Roche (RHHBY) for hard-to-treat cancer therapies.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.maiabiotech.com/news-events/press-releases/detail/141/maia-biotechnology-announces-master-clinical-supply">agreement</a> aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.Checkpoint inhibitors are a type of immunotherapy used to treat cancer. They work by blocking proteins called checkpoints that cancer cells use to evade the immune system.MAIA CEO Vlad Vitoc said that Ateganosine was found to be “highly synergistic and effective” in combination with Roche’s Atezolizumab in preclinical studies.MAIA’s Ateganosine is an investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.Ateganosine is presently being developed as a second or later line of treatment for NSCLC for patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.On Stocktwits, retail sentiment around MAIA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed unchanged at ‘low’ levels.<figure class="image"><img style="aspect-ratio:630/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_10_02_21_AM_png_d32286ea58.webp" alt="MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits" width="630" height="66"><figcaption>MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the new agreement.<stembedurl>https://stocktwits.com/MoneyHelix/message/618266998</stembedurl>Another opined that it's “not bad news.”<stembedurl>https://stocktwits.com/share97/message/618262353</stembedurl><a href="https://stocktwits.com/symbol/MAIA">MAIA stock </a>is down by 11% this year and by over 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/air-india-boeing-crash-emergency-power-system-may-have-deployed-mid-flight/chls3JTRR2d">Air India Boeing Crash: Report Says Emergency Power System May Have Deployed Mid-Flight, Raising Engine Failure Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Equity

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.


This account has been verified as an official MAIA representative.

Verified Account

MAIA Biotechnology

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

MAIA Biotechnology Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$2.20
Prev Close	$1.74
Open	$1.85
Dividend Yield	0.00%
50-Day Moving Average	$1.31
Beta	0.89
Avg. Volume	1.04M
PE Ratio	-2.96

52-Week High	$2.74
52-Week Low	$0.87
Market Capitalization	$64.44M
EPS (Annual)	-$1.05
Price to Book	1,818.18
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MAIA
MAIA Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAIA News

MAIAMAIA Biotechnology Inc